KARTHIK LOGANATHAN

Dr. KARTHIK LOGANATHAN

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
Jayaseelan ChidambaramJayaseelan Chidambaram
Jayaseelan Chidambaram
ARA. Abdul Rahuman
A. Abdul Rahuman
AKA. Vishnu Kirthi
A. Vishnu Kirthi
SMS. Marimuthu
S. Marimuthu
TST. Santhoshkumar
T. Santhoshkumar
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao

15 June 2013 in Bioprocess and Biosystems Engineering
Verified
Journal Article
Closed access
PDF file
KLKARTHIK LOGANATHAN
KARTHIK LOGANATHAN
Gaurav KumarGaurav Kumar
Gaurav Kumar
AKA. Vishnu Kirthi
A. Vishnu Kirthi
ARA. A. Rahuman
A. A. Rahuman
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao

11 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKARTHIK LOGANATHAN
KARTHIK LOGANATHAN
Gaurav KumarGaurav Kumar
Gaurav Kumar
TKTarun Keswani
Tarun Keswani
ABArindam Bhattacharyya
Arindam Bhattacharyya
SCS Sarath Chandar
S Sarath Chandar
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao
The study was planned to screen the marine actinobacterial extract for the protease inhibitor activity and its anti- Pf activity under in vitro and in vivo conditions. Out of 100 isolates, only 3 isolates exhibited moderate to high protease inhibitor activities on trypsin, chymotrypsin and proteinase K. Based on protease inhibitor activity 3 isolates were chosen for further studies. The potential isolate was characterized by polyphasic approach and identified as Streptomyces sp LK3 (JF710608). The lead compound was identified as peptide from Streptomyces sp LK3. The double-reciprocal plot displayed inhibition mode is non-competitive and it confirms the irreversible nature of protease inhibitor. The peptide from Streptomyces sp LK3 extract showed significant anti plasmodial activity (IC50: 25.78 µg/ml). In in vivo model, the highest level of parasitemia suppression (≈45%) was observed in 600 mg/kg of the peptide. These analyses revealed no significant changes were observed in the spleen and liver tissue during 8 dpi. The results confirmed up-regulation of TGF-β and down regulation of TNF-α in tissue and serum level in PbA infected peptide treated mice compared to PbA infection. The results obtained infer that the peptide possesses anti- Pf activity activity. It suggests that the extracts have novel metabolites and could be considered as a potential source for drug development.

1 September 2013 in Asian Pacific Journal of Tropical Medicine
Verified
Journal Article
Open access
SMSampath Marimuthu
Sampath Marimuthu
ARAbdul Abdul Rahuman
Abdul Abdul Rahuman
Jayaseelan ChidambaramJayaseelan Chidambaram
Jayaseelan Chidambaram
AKArivarasan Vishnu Kirthi
Arivarasan Vishnu Kirthi
TSThirunavukkarasu Santhoshkumar
Thirunavukkarasu Santhoshkumar
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao
To assess the acaricidal activity of titanium dioxide nanoparticles (TiO2 NPs) synthesized from flower aqueous extract of Calotropis gigantea(C. gigantea) against the larvae of Rhipicephalus (Boophilus) microplus [R. (B.) microplus] and the adult of Haemaphysalis bispinosa (H. bispinosa). The lyophilized C. gigantea flower aqueous extract of 50 mg was added with 100 mL of TiO(OH)2 (10 mM) and magnetically stirred for 6 h. Synthesized TiO2 NPs were characterized by X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), Scanning electron microscopy (SEM), and Energy dispersive X-ray spectroscopy (EDX). The synthesised TiO2 NPs were tested against the larvae of R. (B.) microplus and adult of H. bispinosa were exposed to filter paper impregnated method. XRD confirmed the crystalline nature of the nanoparticles with the mean size of 10.52 nm. The functional groups for synthesized TiO2 NPs were 1 405.19, and 1 053.45 cm(-1) for -NH2 bending, primary amines and amides and 1 053.84 and 1 078.45 cm(-1) for C-O. SEM micrographs of the synthesized TiO2 NPs showed the aggregated and spherical in shape. The maximum efficacy was observed in the aqueous flower extract of C. gigantea and synthesized TiO2 NPs against R. (B.) microplus (LC50=24.63 and 5.43 mg/L and r(2)=0.960 and 0.988) and against H. bispinosa (LC50= 35.22 and 9.15 mg/L and r(2) = 0.969 and 0.969), respectively. The synthesized TiO2 NPs were highly stable and had significant acaricidal activity against the larvae of R. (B.) microplus and adult of H. bispinosa. This study provides the first report of synthesized TiO2 NPs and possessed excellent anti-parasitic activity.

1 January 2022 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
GKGangarapu Kiran
Gangarapu Kiran
KLKARTHIK LOGANATHAN
KARTHIK LOGANATHAN
SMShree Devi MS
Shree Devi MS
PSP. Sathiyarajeswaran
P. Sathiyarajeswaran
KKK. Kanakavalli
K. Kanakavalli
DKD. Ramesh Kumar
D. Ramesh Kumar
Siddha Medicine is a valuable therapeutic choice which is classically used for treating viral respiratory infections, this principle of medicine is proven to contain antiviral compounds. The study is aimed to execute the In Silico computational studies of phytoconstituents of Siddha official formulation Kabasura Kudineer and novel herbal preparation - JACOM which are commonly used in treating viral fever and respiratory infectious diseases and could be affective against the ongoing pandemic novel corona virus disease SARS-CoV-2. Cresset Flare software was used for molecular docking studies against the spike protein SARS-CoV-2 (PDB ID: 6VSB). Further, we also conducted insilico prediction studies on the pharmacokinetics (ADME) properties and the safety profile in order to identify the best drug candidates by using online pkCSM and SwissADME web servers. Totally 37 compounds were screened, of these 9 compounds showed high binding affinity against SARS-CoV-2 spike protein. All the phytoconstituents were free from carcinogenic and tumorigenic properties. Based on these, we proposed the new formulation called as "SNACK-V" CONCLUSION: Based on further experiments and clinical trials, these formulations could be used for effective treatment of COVID-19.

1 October 2012 in Experimental Parasitology
Verified
Journal Article
Closed access
TSThirunavukkarasu Santhoshkumar
Thirunavukkarasu Santhoshkumar
ARAbdul Abdul Rahuman
Abdul Abdul Rahuman
Asokan BagavanAsokan Bagavan
Asokan Bagavan
SMSampath Marimuthu
Sampath Marimuthu
Jayaseelan ChidambaramJayaseelan Chidambaram
Jayaseelan Chidambaram
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao